Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ines Paule

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Clinical Pharmacokinetics|November 27, 2012
Pharmacodynamic models for discrete dataInes Paule, Pascal Girard, Gilles Freyer, et al.
Clinical Pharmacokinetics|October 17, 2017
Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease PatientsJerry Nedelman, Roland Fisch, Ke Hu, et al.
Drug Metabolism and Pharmacokinetics|May 31, 2016
Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansionWataru Honma, Aurélie Gautier, Ines Paule, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2011
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulationInes Paule, Michel Tod, Emilie Hénin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 29, 2017
Impact of siponimod on vaccination response in a randomized, placebo-controlled studyMike Ufer, Kasra Shakeri-Nejad, Anne Gardin, et al.
Orphanet Journal of Rare Diseases|May 31, 2011
Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimenInes Paule, Hind Sassi, Anoosha Habibi, et al.
Alzheimer'S Research & Therapy|March 6, 2023
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's diseaseAngelika Caputo, Amy Racine, Ines Paule, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Clinical Pharmacokinetics|November 27, 2012
Pharmacodynamic models for discrete dataInes Paule, Pascal Girard, Gilles Freyer, et al.
Clinical Pharmacokinetics|October 17, 2017
Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease PatientsJerry Nedelman, Roland Fisch, Ke Hu, et al.
Drug Metabolism and Pharmacokinetics|May 31, 2016
Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansionWataru Honma, Aurélie Gautier, Ines Paule, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2011
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulationInes Paule, Michel Tod, Emilie Hénin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 29, 2017
Impact of siponimod on vaccination response in a randomized, placebo-controlled studyMike Ufer, Kasra Shakeri-Nejad, Anne Gardin, et al.
Orphanet Journal of Rare Diseases|May 31, 2011
Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimenInes Paule, Hind Sassi, Anoosha Habibi, et al.
Alzheimer'S Research & Therapy|March 6, 2023
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's diseaseAngelika Caputo, Amy Racine, Ines Paule, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.
Pageof 1